Center for Endocrine Tumors Leiden, Leiden University Medical Center, Leiden, The Netherlands.
Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands.
Endocrine. 2020 Jul;69(1):175-187. doi: 10.1007/s12020-020-02308-2. Epub 2020 May 2.
Discharge policies concerning hospitalization after endoscopic pituitary tumor surgery are highly variable. A few studies support fast-track discharge; however, this is not commonplace. Our goal was to report the transition to and evaluate the feasibility, safety, clinical- and patient-reported outcomes and costs of fast-track care in pituitary surgery.
This observational study included 155 patients undergoing pituitary surgery between December 2016 and December 2018. Fast-track care consisted of planned discharge 2-3 days after surgery, followed by daily surveillance by a case manager. All outcomes were compared with patients not eligible for fast-track discharge. The total group (fast-track and non-fast-track) was compared with historic controls (N = 307).
A total of 79/155 patients (51%) were considered eligible for fast-track discharge, of whom 69 (87%) were discharged within 3 days. The total group was discharged more often within 3 days compared with historic controls (49 vs. 20%, p < 0.001), the total length of stay did not differ (5.3 vs. 5.7 days, p = 0.363). Although the total group had more readmissions compared with historic controls (17 vs. 10%, p = 0.002), no life-threatening complications occurred after discharge. On average, clinical- and patient-reported outcomes improved over time, both in the fast-track and non-fast-track groups. The mean overall costs within 30 days after surgery did not differ between the total group € 9992 (SD € 4562) and historic controls € 9818 (SD € 3488) (p = 0.649).
A stratified fast-track care trajectory with enhanced postoperative outpatient surveillance after pituitary tumor surgery is safe and feasible. As expected, costs of the fast-track were lower than the non-fast-track group, however we could not prove overall cost-effectiveness compared with the historic controls.
内镜下垂体瘤手术后的出院政策差异很大。有一些研究支持快速通道出院,但这种情况并不常见。我们的目标是报告向快速通道护理的转变,并评估其在垂体瘤手术中的可行性、安全性、临床和患者报告的结果以及成本。
这项观察性研究纳入了 2016 年 12 月至 2018 年 12 月期间接受垂体瘤手术的 155 名患者。快速通道护理包括术后 2-3 天计划出院,随后由个案经理进行日常监测。所有结果均与不符合快速通道出院条件的患者进行比较。总组(快速通道和非快速通道)与历史对照组(N=307)进行比较。
共有 155 名患者中的 79 名(51%)被认为符合快速通道出院条件,其中 69 名(87%)在 3 天内出院。总组在 3 天内出院的比例高于历史对照组(49%比 20%,p<0.001),总住院时间无差异(5.3 天比 5.7 天,p=0.363)。尽管总组的再入院率高于历史对照组(17%比 10%,p=0.002),但出院后没有发生危及生命的并发症。平均而言,快速通道和非快速通道组的临床和患者报告的结果都随着时间的推移而改善。术后 30 天内的总总体成本在总组中为 9992 欧元(SD=4562),在历史对照组中为 9818 欧元(SD=3488)(p=0.649)。
分层的快速通道护理轨迹,并在垂体瘤手术后加强门诊随访是安全且可行的。不出所料,快速通道的成本低于非快速通道组,但我们无法证明与历史对照组相比具有总体成本效益。